CZ20011657A3 - Nové piperazinové a piperidinové sloučeniny, způsob jejich přípravy a jejich pouľití - Google Patents

Nové piperazinové a piperidinové sloučeniny, způsob jejich přípravy a jejich pouľití

Info

Publication number
CZ20011657A3
CZ20011657A3 CZ20011657A CZ20011657A CZ20011657A3 CZ 20011657 A3 CZ20011657 A3 CZ 20011657A3 CZ 20011657 A CZ20011657 A CZ 20011657A CZ 20011657 A CZ20011657 A CZ 20011657A CZ 20011657 A3 CZ20011657 A3 CZ 20011657A3
Authority
CZ
Czechia
Prior art keywords
preparation
piperidine compounds
novel piperazine
piperazine
novel
Prior art date
Application number
CZ20011657A
Other languages
English (en)
Other versions
CZ299774B6 (cs
Inventor
Roelof W. Feenstra
Der Heijden Johannes A. M. Van
Johannes Mos
Stephen K. Long
Gerben M. Visser
Cornelis G. Kruse
Scharrenburg Gustaaf J. M. Van
Gerrit P. Toorop
Original Assignee
Duphar International Research B. V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8234340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CZ20011657(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duphar International Research B. V. filed Critical Duphar International Research B. V.
Publication of CZ20011657A3 publication Critical patent/CZ20011657A3/cs
Publication of CZ299774B6 publication Critical patent/CZ299774B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CZ20011657A 1998-11-13 1999-11-10 Nové piperazinové a piperidinové slouceniny, zpusob jejich prípravy a jejich použití CZ299774B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98203871 1998-11-13

Publications (2)

Publication Number Publication Date
CZ20011657A3 true CZ20011657A3 (cs) 2001-10-17
CZ299774B6 CZ299774B6 (cs) 2008-11-19

Family

ID=8234340

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20011657A CZ299774B6 (cs) 1998-11-13 1999-11-10 Nové piperazinové a piperidinové slouceniny, zpusob jejich prípravy a jejich použití

Country Status (27)

Country Link
US (1) US6780864B1 (cs)
EP (1) EP1131308B1 (cs)
JP (1) JP3638874B2 (cs)
KR (1) KR100619465B1 (cs)
CN (1) CN1225462C (cs)
AR (1) AR021256A1 (cs)
AT (1) ATE267183T1 (cs)
AU (1) AU756470B2 (cs)
BR (1) BR9915293B1 (cs)
CA (1) CA2350137C (cs)
CZ (1) CZ299774B6 (cs)
DE (1) DE69917478T2 (cs)
DK (1) DK1131308T3 (cs)
DZ (1) DZ2934A1 (cs)
ES (1) ES2217833T3 (cs)
HU (1) HUP0104922A3 (cs)
IL (2) IL143028A0 (cs)
MX (1) MXPA01004854A (cs)
NO (1) NO318888B1 (cs)
NZ (1) NZ511584A (cs)
PL (1) PL193685B1 (cs)
RU (1) RU2225406C2 (cs)
SI (1) SI1131308T1 (cs)
SK (1) SK285648B6 (cs)
TW (1) TWI252230B (cs)
UA (1) UA71590C2 (cs)
WO (1) WO2000029397A1 (cs)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73981C2 (en) 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
WO2001085168A1 (en) * 2000-05-12 2001-11-15 Solvay Pharmaceuticals B.V. Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders
AU6392701A (en) * 2000-05-12 2001-11-20 Solvay Pharm Bv Piperazine and piperidine compounds
HUP0302761A2 (hu) * 2000-11-14 2003-12-29 Merck Patent Gmbh. Kombinált szelektív dopamin D2 receptor antagonista és 5-HT1A receptor agonista hatású vegyületek alkalmazása gyógyszerkészítmények előállítására
AR034206A1 (es) * 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
US6800648B2 (en) * 2001-04-26 2004-10-05 Wyeth Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-1,6,9-trioxa-3-AZA-cyclopenta[a]naphthalen-2-one
US6743796B2 (en) * 2001-05-07 2004-06-01 Wyeth Piperazinyl-isatins
EP1408976B3 (en) 2001-07-20 2010-08-25 Psychogenics Inc. Treatment for attention-deficit hyperactivity disorder
US7872030B2 (en) 2001-07-26 2011-01-18 Merck Patent Gmbh Use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
EP1336406A1 (en) * 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
WO2004000837A1 (ja) * 2002-06-25 2003-12-31 Sumitomo Pharmaceuticals Co., Ltd. 新規なベンズオキサゾリノン誘導体
US7435738B2 (en) 2003-08-18 2008-10-14 Solvay Pharmaceuticals, Inc. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
EP1595542A1 (en) * 2004-03-26 2005-11-16 Solvay Pharmaceuticals B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
US7596407B2 (en) 2004-03-26 2009-09-29 Solvay Pharmaceuticals, B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
WO2005118561A1 (en) * 2004-05-27 2005-12-15 Ucb, S.A. Benzoxazolone derivatives, processes for preparing them and their uses
US7405216B2 (en) 2004-08-18 2008-07-29 Solvay Pharmaceuticals, B.V. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7964604B2 (en) 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
US7423040B2 (en) 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
US7750013B2 (en) 2005-08-22 2010-07-06 Solvay Pharmaceuticals, B.V. N-oxides as prodrugs of piperazine and piperidine derivatives
AR058022A1 (es) * 2005-08-22 2008-01-23 Solvay Pharm Bv Derivados de benzooxazoles, composiciones farmaceuticas y su uso para el tratamiento de desordenes del sistema nervioso.
WO2007023141A1 (en) * 2005-08-22 2007-03-01 Solvay Pharmaceuticals B.V. N-oxides as prodrugs of piperazine & piperidine derivatives
US8106056B2 (en) 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
US7786126B2 (en) 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
UY32935A (es) 2009-10-12 2011-05-31 Abbott Healthcare Products Bv Polimorfos de pardoprunox
WO2018039642A1 (en) 2016-08-26 2018-03-01 Exciva Ug (Haftungsbeschränkt) Compositions and methods thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2567884B1 (fr) 1984-07-19 1987-03-06 Roussel Uclaf Nouveaux derives de l'indole, leur preparation, leur application comme medicaments et les compositions les renfermant
EP0190472B1 (en) * 1984-12-21 1989-07-12 Duphar International Research B.V New pharmaceutical compositions having anti-psychotic properties
ATE81975T1 (de) * 1984-12-21 1992-11-15 Duphar Int Res Arzneimittel mit psychotroper wirkung.
DK148392D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
ZA954689B (en) 1994-06-08 1996-01-29 Lundbeck & Co As H 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines
JP3155008B2 (ja) 1994-07-26 2001-04-09 ファイザー・インコーポレーテッド セロトニンアゴニストおよびアンタゴニストとしての４−インドール誘導体
ATE340173T1 (de) * 1996-03-29 2006-10-15 Duphar Int Res Piperazin- und piperidin- derivate
EP0900792B1 (en) * 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists

Also Published As

Publication number Publication date
US6780864B1 (en) 2004-08-24
TWI252230B (en) 2006-04-01
EP1131308A1 (en) 2001-09-12
AU1270900A (en) 2000-06-05
BR9915293A (pt) 2001-08-07
SK285648B6 (sk) 2007-05-03
AR021256A1 (es) 2002-07-03
SI1131308T1 (en) 2004-10-31
DE69917478D1 (de) 2004-06-24
EP1131308B1 (en) 2004-05-19
ATE267183T1 (de) 2004-06-15
JP2002530276A (ja) 2002-09-17
SK6492001A3 (en) 2001-10-08
UA71590C2 (en) 2004-12-15
NO20012339D0 (no) 2001-05-11
KR100619465B1 (ko) 2006-09-05
MXPA01004854A (es) 2005-07-25
BR9915293B1 (pt) 2011-11-01
HUP0104922A2 (en) 2002-08-28
CN1378540A (zh) 2002-11-06
DE69917478T2 (de) 2004-09-16
CA2350137A1 (en) 2000-05-25
NO20012339L (no) 2001-05-11
JP3638874B2 (ja) 2005-04-13
DK1131308T3 (da) 2004-06-28
PL193685B1 (pl) 2007-03-30
IL143028A0 (en) 2002-04-21
IL143028A (en) 2006-12-10
ES2217833T3 (es) 2004-11-01
CA2350137C (en) 2008-04-22
RU2225406C2 (ru) 2004-03-10
KR20010080995A (ko) 2001-08-25
PL347635A1 (en) 2002-04-22
NZ511584A (en) 2003-01-31
WO2000029397A1 (en) 2000-05-25
AU756470B2 (en) 2003-01-16
DZ2934A1 (fr) 2004-03-15
CZ299774B6 (cs) 2008-11-19
CN1225462C (zh) 2005-11-02
HK1039489A1 (en) 2002-04-26
HUP0104922A3 (en) 2003-05-28
NO318888B1 (no) 2005-05-18

Similar Documents

Publication Publication Date Title
CZ20011657A3 (cs) Nové piperazinové a piperidinové sloučeniny, způsob jejich přípravy a jejich pouľití
HUP0300567A3 (en) Process for preparation of novel piperazine derivatives
HUP0102556A3 (en) Benzenesulfonamide-derivatives and their use as medicaments and process for the preparation of the compounds
IL136086A0 (en) New composition of matter
PL316613A1 (en) Novel derivatives of piperazine, methods of obtaining them and agents containing such derivatives
ZA984127B (en) New composition of matter
PL338075A1 (en) Derivatives of piperazine
PL316382A1 (en) Novel derivatives of piperidine
CZ20012130A3 (cs) Piperazinový derivát, způsob jeho výroby a pouľití
IL126295A0 (en) New piperazine and piperidine compounds
HUP9802447A3 (en) Piperazine derivatives process for their preparation and their use as 5-ht1a antagonists
PL342817A1 (en) Novel derivatives of dihydroxyhexanic acid
PL312692A1 (en) New derivatives of dialkoxy-pyridinol-benzimidazole
IL146023A0 (en) Novel synthesis and crystallization of piperazine ring-containing compounds
IL126426A0 (en) Process for the preparation of corroles several such new compounds including chiral derivatives and the use thereof
PL333323A1 (en) Derivatives of piperidine
PL345999A1 (en) Crystalline forms of osanetant
HUP0104159A3 (en) Novel antihistaminic piperidine derivatives and intermediates and process for the preparation thereof and medicaments containing them
HUP0103309A3 (en) Novel salts of n-tert-butylhydroxylamine and preparation thereof
AU5553200A (en) Process for the preparation of paroxetine and structurally related compounds
IL108595A0 (en) Novel derivatives of tetramethylcyclopropane
PL344872A1 (en) Novel formulation containing paroxetine
AU1459500A (en) Dihydropyridine compounds and methods of use
IL139594A0 (en) Novel formulation containing paroxetine
HUP0101215A3 (en) Chrystalline form of paroxetine

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of fee

Effective date: 20121110